CONCURRENT CLARITHROMYCIN AND CYCLOSPORINE-A TREATMENT

Although macrolides have been associated with significant pharmacokine tic interactions, clarithromycin is considered to have a low interacti on capacity. In this study, six transplant recipients treated with cyc losporin A also received clarithromycin, In all patients, the dose of cyclosporin A had to be reduced by a mean of 33% per day depending on the macrolide dose, Normalization of the dosage parameters began on th e fourth day after stopping clarithromycin treatment. Go-administratio n of cyclosporin A and clarithromycin may lead to increases in whole b lood cyclosporin levels, and appropriate dose reductions should be con sidered.